Abdel Nasser Hosein1, Muhammad Shaalan Beg2. 1. Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2. Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. Muhammad.beg@utsouthwestern.edu.
Abstract
PURPOSE OF REVIEW: Pancreatic adenocarcinoma is a leading cause of cancer mortality in western countries with a uniformly poor prognosis. Unfortunately, there has been little in the way of novel therapeutics for this malignancy over the last several decades. Derangements in metabolic circuitry favoring excess glycolysis are increasingly recognized as a key hallmark of cancer. RECENT FINDINGS: The role of alterations in glutamine metabolism in pancreatic tumor progression has been elucidated in animal models and human cells lines, and there has been considerable interest in exploiting these aberrations for the treatment of pancreatic cancer. Other strategies targeting NQO1/GLS1 inhibition, NAD+ synthesis, and TCA cycle intermediates are being actively studied in the clinic. Aberrant metabolism in pancreatic cancer poses a unique therapeutic strategy. We review preclinical and clinical studies looking to exploit alterations in the metabolic circuitry of pancreatic cancer.
PURPOSE OF REVIEW: Pancreatic adenocarcinoma is a leading cause of cancer mortality in western countries with a uniformly poor prognosis. Unfortunately, there has been little in the way of novel therapeutics for this malignancy over the last several decades. Derangements in metabolic circuitry favoring excess glycolysis are increasingly recognized as a key hallmark of cancer. RECENT FINDINGS: The role of alterations in glutamine metabolism in pancreatic tumor progression has been elucidated in animal models and human cells lines, and there has been considerable interest in exploiting these aberrations for the treatment of pancreatic cancer. Other strategies targeting NQO1/GLS1 inhibition, NAD+ synthesis, and TCA cycle intermediates are being actively studied in the clinic. Aberrant metabolism in pancreatic cancer poses a unique therapeutic strategy. We review preclinical and clinical studies looking to exploit alterations in the metabolic circuitry of pancreatic cancer.
Authors: Meghan J Seltzer; Bryson D Bennett; Avadhut D Joshi; Ping Gao; Ajit G Thomas; Dana V Ferraris; Takashi Tsukamoto; Camilo J Rojas; Barbara S Slusher; Joshua D Rabinowitz; Chi V Dang; Gregory J Riggins Journal: Cancer Res Date: 2010-11-02 Impact factor: 12.701
Authors: Nida S Awadallah; Donna Dehn; Raj J Shah; S Russell Nash; Yang K Chen; David Ross; Joel S Bentz; Kenneth R Shroyer Journal: Appl Immunohistochem Mol Morphol Date: 2008-01
Authors: Ralph J DeBerardinis; Anthony Mancuso; Evgueni Daikhin; Ilana Nissim; Marc Yudkoff; Suzanne Wehrli; Craig B Thompson Journal: Proc Natl Acad Sci U S A Date: 2007-11-21 Impact factor: 11.205
Authors: Aimable Nahimana; Antoine Attinger; Dominique Aubry; Peter Greaney; Christopher Ireson; Annemette V Thougaard; Jette Tjørnelund; Keith M Dawson; Marc Dupuis; Michel A Duchosal Journal: Blood Date: 2009-02-05 Impact factor: 22.113
Authors: Molly A Silvers; Stanislaw Deja; Naveen Singh; Robert A Egnatchik; Jessica Sudderth; Xiuquan Luo; Muhammad S Beg; Shawn C Burgess; Ralph J DeBerardinis; David A Boothman; Matthew E Merritt Journal: J Biol Chem Date: 2017-09-15 Impact factor: 5.486
Authors: Mathias T Rosenfeldt; Jim O'Prey; Jennifer P Morton; Colin Nixon; Gillian MacKay; Agata Mrowinska; Amy Au; Taranjit Singh Rai; Liang Zheng; Rachel Ridgway; Peter D Adams; Kurt I Anderson; Eyal Gottlieb; Owen J Sansom; Kevin M Ryan Journal: Nature Date: 2013-12-04 Impact factor: 49.962
Authors: Jaekyoung Son; Costas A Lyssiotis; Haoqiang Ying; Xiaoxu Wang; Sujun Hua; Matteo Ligorio; Rushika M Perera; Cristina R Ferrone; Edouard Mullarky; Ng Shyh-Chang; Ya'an Kang; Jason B Fleming; Nabeel Bardeesy; John M Asara; Marcia C Haigis; Ronald A DePinho; Lewis C Cantley; Alec C Kimmelman Journal: Nature Date: 2013-03-27 Impact factor: 49.962
Authors: Qianlei Yang; Rui Yan; Yuemei Mo; Haixuan Xia; Hanyi Deng; Xiaojuan Wang; Chunchun Li; Koichi Kato; Hengdong Zhang; Tingxu Jin; Jie Zhang; Yan An Journal: Int J Environ Res Public Health Date: 2022-07-01 Impact factor: 4.614
Authors: Christine A Juliana; Juxiang Yang; Corey E Cannon; Austin L Good; Matthew W Haemmerle; Doris A Stoffers Journal: Mol Metab Date: 2018-08-01 Impact factor: 7.422
Authors: Dan Wang; Yawei Bi; Lianghao Hu; Yongde Luo; Juntao Ji; Albert Z Mao; Craig D Logsdon; Ellen Li; James L Abbruzzese; Zhaoshen Li; Vincent W Yang; Weiqin Lu Journal: Cell Commun Signal Date: 2019-02-28 Impact factor: 5.712
Authors: Rong Tang; Xiaomeng Liu; Wei Wang; Jie Hua; Jin Xu; Chen Liang; Qingcai Meng; Jiang Liu; Bo Zhang; Xianjun Yu; Si Shi Journal: Front Oncol Date: 2021-04-12 Impact factor: 6.244